11MO Final data from a phase II study (TACTI-002) of eftilagimod alpha (soluble LAG-3) and pembrolizumab in 2nd-line metastatic NSCLC pts resistant to PD-1/PD-L1 inhibitors

M. Majem, M.D. Forster, M.G. Krebs, J. Peguero, T.D. Clay, E. Felip, W. Iams, P. Roxburgh, B. Doger de Spéville, P. Bajaj,

Journal of Thoracic Oncology · 2023 · 10 citations · 0 references

DOIFull text

Open access

Concepts